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Since the beginning of the HIV burden, Visceral Leishmaniasis (VL)/HIV co-infection has
been diagnosed not only in areas where VL is endemic (Latin America, India, Asia, Southern
Europe), but also in North America, were it is considered an opportunistic disease. Clinical
presentation, diagnostic tests sensitivity and treatment response in this population differs
from VL alone.
Objectives: To evaluate factors related to an unfavorable outcome in patients with VL/HIV
diagnosis in a reference center in northeast Brazil.
Methods: Co-infected patients, diagnosed from 2010 to 2012, were included. Data from med-
ical  records were collected until one year after VL treatment completion.
Results: Forty-two HIV-infected patients were included in the study. Anemia, leukopenia,
and  thrombocytopenia were present in 95%, 70.7%, and 63.4%, respectively. Mean T CD4+
(LTCD4) lymphocyte count was 183 cells/dL. Highly active antiretroviral therapy (HAART) was
being used by 54.7% of cases. A favorable outcome was seen in 71.4% of cases. Recurrence of
VL  occurred in nine patients and deaths were secondary to infectious complications (3/42
patients). Very low LTCD4 count (<100 cells/dL) was the only independent variable associated
with an unfavorable outcome in multivariate analysis (p = 0.03).Conclusion: Low LTCD4 count at presentation was associated with unfavorable outcome in
VL/HIV patients.
© 2015 Elsevier Editora Ltda. All rights reserved.
immunodeﬁciency virus (HIV) has been diagnosed not only inntroductionisceral Leishmaniasis (VL), also known as kala-azar, is
sually caused by Leishmania (Leishmania) chagasi, and is
haracterized by fever, hepatosplenomegaly, pancytopenia,
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.substantial weight loss, and hypergammaglobulinemia. Since
the beginning of the HIV burden, co-infection of VL and humanEP: 60192-205, Fortaleza, Ceará, Brazil.
areas where VL is endemic (Latin America, India, Asia, South-
ern Europe), but also in North America, were it is considered an
opportunistic disease. In Brazil, some authors have reported
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Table 1 – Anti-leishmania treatment in visceral
leishmaniasis/HIV infected patients diagnosed from
Jan/2010 to Dec/2012 in a reference center in northeast
Brazil.
Initial therapy
No. of patients
(%)
Reason for
changing therapy
No. of patients (%)
Second therapy
Amphotericin B
deoxycholate
37 (88.1%)
Renal
insufﬁciency
10 (27%)
Liposomal
amphotericin
B
Liposomal
amphotericin
B
3 (7.3%)
Not  applied –
Pentavalent
antimonial
HIV  diagnosis
1 (2.4%)
Amphotericin
B652  b r a z j i n f e c t d 
5% prevalence in the beginning of the 21st century.1 In fact,
the risk of developing VL appears to be considerably higher
in the HIV-infected population.2 This association raised a lot
of concerns and questions. Many  studies showed that clini-
cal presentation in this population differs from VL alone.2,3
The sensitivity and speciﬁcity of the diagnostic tests seems to
be different as well. Parasitologic direct visualization tests are
more sensitive than in the HIV negative population because
of the higher parasite burden observed in VL/HIV individuals.4
Also, there is much evidence that VL/HIV patients have poorer
response to treatment and higher mortality rates.5–9 These
data suggest that VL/HIV co-infection should be considered
an emergent disease and that efforts must be done to a better
understanding of this condition.
The aim of this study was to evaluate factors that inﬂu-
enced the outcome in patients with VL/HIV diagnosis in a
reference center in northeast Brazil.
Materials  and  methods
This retrospective cohort study was conducted at Hospi-
tal São José (HSJ), a state reference center for infectious
diseases in Ceará, northeast Brazil. All adult (>18 years)
patients diagnosed with VL/HIV co-infection from Jan/2010
to Dec/2012 were included and data from their medical
records were collected until one year after VL treatment
completion. Sociodemographic, clinical, laboratory, and treat-
ment data were abstracted. Patients were classiﬁed into
two groups for comparison: favorable and unfavorable out-
come. Unfavorable outcome was considered when death or
VL relapse occurred. According to the study inclusion cri-
teria, the presence of diagnostic conﬁrmation of VL (either
parasitologic or serologic – DAT, ELISA, or rK39) and HIV
(serologic or PCR) infection was necessary. The HIV diagnosis
was in accordance to the Brazilian HIV Diagnosis Guide-
line, October/2009.10 Approval for this study was obtained
from the Ethical Review Board of HSJ (CEP/HSJ judgment no.
173.415/2012).
The statistical analysis was performed using STATA 12.
Student’s t-test and Mann–Whitney–Wilcoxon test were used
to compare means and medians of continuous variables,
respectively. Some of these were categorized to allow statis-
tical analyses. Chi-square tests were used for the two patient
groups comparison in the univariate analysis. All variables
with a p-value <0.20 were included in a multivariate logis-
tic regression model. A signiﬁcant association was considered
with a p-value <0.05.
Results
During the study period, 635 VL cases were diagnosed at HSJ.
Forty-two (6.6%) were HIV-infected adult patients and were,
therefore, included in the study. All of them had clinical VL
diagnosis conﬁrmed either by parasitologic tests (bone mar-
row aspiration with direct exam – 80.5%) or serologic methods
(rK39 antibodies – 66.6%) from January/2010 to December/2012.
In 14 patients (34%), the diagnosis was conﬁrmed by the
two methods. Patients were mainly young man  (88.1% male,
mean age 35 years), who lived in urban area (76%). Most of1 (2.4%) deoxycholate
them presented with fever, weight loss, adynamia, and hep-
atosplenomegaly (Fig. 1).
Laboratory data showed anemia in 95% (mean hemoglobin
level 7.8 g/dL), leukopenia in 70.7% (mean leukocytes 1756
cells/dL), and thrombocytopenia in 63.4% (mean platelets
count 62,792/dL) of the patients. Abnormal levels of creati-
nine and albumin were also noted, although least frequently.
T CD4+ (LTCD4) Lymphocyte count at VL diagnosis was low
(mean LTCD4 183 cells/dL) and in 61.9% patients it was below
200 cells/dL. Viral load was detectable in 54.7% of cases, even
though 73.8% were on highly active antiretroviral therapy
(HAART), with median therapy duration of 7.6 months.
Therapy with amphotericin B deoxycholate was initi-
ated in 88.1% of the participants; 27% were subsequently
switched to the liposomal formulation due to adverse events.
One of the patients died before initiating treatment and
another patient initiated with pentavalent antimonial and
was switched to amphotericin B deoxycholate after being
diagnosed as HIV positive. Table 1 summarizes VL treatment
options of the studied patients and the reasons for therapy
change.
A favorable outcome after one-year follow-up was seen
in 71.4% of cases. Recurrence of VL was diagnosed in nine
patients, with mean time to recurrence of 38 days. All deaths
were secondary to infectious complications (3/42 patients).
One of them had pneumonia with severe respiratory insuf-
ﬁciency and the others died because of septic shock.
In order to identify factors that were associated with an
unfavorable outcome, patients were classiﬁed into two groups.
Table 2 shows univariate analysis of epidemiological, clinical,
and laboratory data. The presence of very low levels of LTCD4
(<100 cells/dL) was the only variable with signiﬁcant differ-
ence between the two groups (p < 0.05). This variable, along
with time of VL/HIV diagnosis, presence of cough, leukope-
nia, thrombocytopenia, very low platelets count (<50,000), very
low albumin level (≤2.5 mg/dL), and HAART before VL diag-
nosis were selected for inclusion into the logistic regression
model (p < 0.2). Very low LTCD4 count was the only indepen-
dent predictor of an unfavorable outcome in the ﬁnal model
(p = 0.03).
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Table 2 – Evaluation of visceral leishmaniasis/HIV co-infection outcome in patients diagnosed from Jan/2010 to Dec/2012
in a reference center in northeast Brazil – univariate analysis.
Variables Favorable outcome Unfavorable outcome p
Gender
Male 26 (86.7%) 11 (91.7%) 0.55
Female 4 (13.3%) 1 (8.3%)
Mean age (years) 34.8 (sd ±10.1) 36.2 (sd ±8.3) 0.33
Age category
>50 yo 3 (10%) 1 (8.3%)
≤50 yo 27 (90%) 11 (91.7%) 0.68
Time of VL diagnosis
Before HIV diagnosis 2 (16.6%) 0
After HIV diagnosis 7 (58.3%) 17 (56.6%) 0.05
Concomitant to HIV diagnosis 3 (25%) 13 (43.3%)
Presence of cough
Yes 13 (43.3%) 8 (66.6%) 0.15
No 17 (56.6%) 4  (33.3%)
Presence of bleeding
Yes 3 (10%) 3 (25%) 0.21
No 27 (90%) 9 (75%)
Presence of anemia
Yes 27 (93.1%) 12 (100%) 0.49
No 2 (6.9%) 0
Mean hemoglobin (g/dL) 7.9 (sd ±1.4) 7.6 (sd ±1.3) 0.28
Hemoglobin category
>7 g/dL 22  (73.3%) 7  (58.3%) 0.46
≤7 g/dL 8 (26.7%) 5 (41.7%)
Presence of leukopenia
Yes 18 (62.1%) 11 (70.7%) 0.05
No 11 (37.9%) 12 (29.3%)
Mean leukocyte (cells/dL) 1824 (sd ±887) 1644 (sd ±952) 0.30
Leukocytes category
>1000 26 (86.7%) 9 (75%) 0.54
≤1000 4 (13.3%) 3 (25%)
Presence of thrombocytopenia
Yes 16 (55.2%) 10 (88.3%) 0.08
No 13 (44.8%) 2 (16.7%)
Mean platelets (no./dL) 70,250 (sd ±40,070) 50,860 (sd ±33,960) 0.89
Platelets category
>50,000 25 (83.3%) 7 (58.3%) 0.08
≤50,000 5 (16.7%) 5 (41.7%)
Creatinine
Normal 23 (79.3%) 9 (75%) 0.53
Elevated 6 (20.7%) 3 (25%)
Mean creatinine (mg/dL) 1.13 (sd ±0.7) 1.1 (sd ±0.8) 0.45
Creatinine level >2 times normal
Yes 1 (4%) 1 (8.3%) 0.55
No 24 (96%) 11 (91.7%)
Presence of hypoalbuminemia
Yes 9 (60%) 7 (77.8%) 0.33
No 6 (40%) 2 (22.2%)
Mean albumin (mg/dL) 3.1 (sd ±0.9) 2.5 (sd ±0.8) 0.09
Albumin category
>2.5 10 (76.9%) 3 (33.3%) 0.05
≤2.5 3 (23.1%) 6 (66.7%)
Mean LTCD4 (cells/dL) 210.8 (sd ±162) 95.7 (sd ±102) 0.03
Low LTCD4 (<200 cells/dL)
Yes 19 (65.5%) 7 (87.5%) 0.22
No 10 (34.5%) 1 (12.5%)
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Table 2 (Continued)
Variables Favorable outcome Unfavorable outcome p
Very low LTCD4 (<100 cells/dL)
Yes 9 (34.6%) 6 (75%) 0.04
No 17 (65.4%) 2 (25%)
Mean viral load (copies/dL) 66,224 (sd ±16,469) 99,607 (sd ±15,467) 0.31
Undetectable viral load
Yes 4 (18.2%) 2 (28.6%) 0.55
No 18 (81.8%) 5 (71.4%)
HAART previous to VL diagnosis
Yes 16 (76.2%) 4 (50%) 0.18
No 5 (23.8%) 4 (50%)
–83) Median duration of HAART use (months) 33.3 (0
Total patients 30 
Discussion
From Jan/2010 to Dec/2012, 1650 VL cases were conﬁrmed in
the state of Ceará11; 635 (38.4%) were diagnosed in HSJ. This
data shows the importance of HSJ as a reference center for
the diagnosis of this disease in our state. However, the preva-
lence of VL-HIV co-infection among VL patients diagnosed
in HSJ was slightly higher (6.6%) than data shown in other
Brazilian studies. Botelho et al. reported a prevalence of 5%
of this co-infection among VL conﬁrmed cases, while another
group showed an even lower prevalence (1.1%).1,12 In both
studies data were collected from governmental disease notiﬁ-
cation database, which gathers information from a variety of
healthcare facilities. HSJ, in contrast, is an infectious disease
reference center and, therefore, concentrate not only VL but
also the HIV infection cases in the state. This could explain
this higher prevalence shown in our study.
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Fig. 1 – Prevalence of clinical ﬁndings in visceral leishmaniasis/H
in a reference center in northeast Brazil.4.6 (0–65.3) 0.34
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Most of the participants had their VL diagnosis conﬁrmed
with parasitologic tests, with only 66% showing positive sero-
logic exams. Deniau et al. and Cota et al. observed similar
results with 60% and 54% positive serologic tests, respectively,
in VL/HIV infected individuals. These ﬁndings suggest that
parasitologic diagnostic methods should be preferred in this
speciﬁc population.13,14
Most of the cases were from urban areas. This is con-
sistent with the trend toward VL urbanization observed in
many  countries, including Brazil. This urbanization process
has been noted since the end of the ninetieth decade. Poverty
and scarce raining seasons leading to intense internal migra-
tion from rural to urban areas are important factors that may
explain this occurrence.15–18
Although some authors have shown atypical clinical
2,3,14,18,19presentation in VL/HIV patients, manifestations at
unusual sites such as skin, lungs, and the gastrointestinal tract
were not observed in our study. Classical symptoms (fever,
l findings
visceral leishmaniasis/HIV infected
2010 to Dec/2012 in a reference
rtheast Brazil
Adynamia Splenomegaly
Cough Bleeding
tients: 42
IV infected patients diagnosed from Jan/2010 to Dec/2012
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eight loss, and hepatosplenomegaly) were more  prevalent;
 result also found in other Brazilian series.6,20
Even though our study sample consisted of only VL/HIV
o-infected patients, both mean hemoglobin (7.8 g/dL) and
latelets levels (62,792/dL) were similar to those found in
ublished series describing HIV negative VL cases. In large
eries of patients with VL from India, average hemoglobin
evel varied from 7.8 to 8.3 g/dL, and mean platelet count was
09,000 (±82.3). Mean leukocyte level varied from 2.8 × 103/L
o 4 × 103/L, which was higher than the value found in our
tudy.21 VL pancytopenia has been well studied. The cause of
nemia is probably multifactorial: immune-mediated mech-
nism, alteration of red blood cells membrane permeability,
emolysis, and hypersplenism. The former is possibly the
ain explanation for low leukocyte and platelet counts.22 In
he HIV population, Leishmaniasis promotes an increase in
IV load leading to more  rapid decrease in LTCD4 cell count
nd progression to AIDS. This ﬁnding and other factors related
o the virus itself can play an important role in more  severe
eukopenia in this co-infected population.7
Mean LTCD4 count at VL presentation varies widely
n published data, although most patients have profound
mmunosuppression, usually with LTCD4 counts below 200
ells/dL and up to half of cases with less than 100
ells/dL.5,6,23,24 In our study, 61.9% of the participants had
elow 200 cells/dL but only 44% had very low LTCD4 counts
<100 cells/dL). This could be due to the high frequency of
AART use (73.8%), even though incomplete adherence was
ound in some cases.
Amphotericin B deoxycholate was the drug of choice in
8.1% of patients and only 7.3% had their treatment initiated
ith the liposomal formulation. This ﬁnding is in accordance
ith the Brazilian Ministry of Health recommendation at that
ime.12 This guideline was modiﬁed in September 2013 based
n plenty of evidence demonstrating the beneﬁts of the lipo-
omal formulation over other drug therapies. Since that time,
iposomal amphotericin B is the drug of choice for the treat-
ent of VL/HIV patients in Brazil.25
HIV infection was frequently associated with a poor out-
ome in VL series from India, Brazil, and Ethiopia. Mortality
ates are usually higher than in the HIV negative cases
8.7–23% versus 1–5%).5,8,14,26,27 In our series the mortality
ate for the co-infected patients was 7.1%. This intermediate
alue was below the usually expected rate but still higher
han the mortality rate seen in HIV negative cases.
Almost 29% of patients had an unfavorable outcome. Very
ow LTCD4 count (<100 cells/dL) at presentation was the only
ariable related to death/relapse. Other authors also found
his association.7,14,23 In one study from Ethiopia, a higher
isk of relapse was demonstrated even with LTCD4 counts
etween 100 and 200 cells/dL.28 The severe immunosup-
ression state may explain the frequent relapses and VL
ssociated complications. Persistence of the parasite in lym-
hoid tissue is a consequence of inability to control Leishmania
eplication through LTCD4 mediated cellular response. Treat-
ng VL patients with anti-leishmanial therapy is associated
ith recovery of lymphopoietic tissue functions.29 However,n HIV-infected individuals this reconstitution is not always
he case and, indeed, relapses have been described even when
TCD4 counts were above 200 cells/dL.6,28 These features are in
15;1 9(6):651–656 655
accordance with the ﬁndings of Berenguer et al. who  reported
a lower risk of VL relapse only when LTCD4 counts were above
350 cells/dL.30 Despite the decrease in relapse risk with HAART
use, many  authors have reported that it appears to be only par-
tially protective, suggesting that the actual goal should be to
achieve the highest levels of LTCD4 possible.6,7,28
In conclusion, our data demonstrate that low LTCD4 level
at presentation was associated with unfavorable outcome in
VL/HIV co-infected patients. Besides all the questions raised
about factors associated with mortality and relapse in this
population, the initiation of HAART as early as possible seems
to be a reasonable measure to reduce complications. Also, a
better understanding of this emergent concurrent infection is
extremely important to guide adequate management of the
co-infected patients and achievement of lower relapse and
death rates.
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